Advertisement

Topics

AZ and Merck enter Lynparza alliance; Merck pays $1.6bn up front

15:40 EDT 28 Jul 2017 | Elsevier Business Intelligence

AstraZeneca PLC and Merck & Co. Inc. agreed to co-develop and commercialize AZ’s poly ADP ribose (PARP) inhibitor Lynparza ...

Original Article: AZ and Merck enter Lynparza alliance; Merck pays $1.6bn up front

NEXT ARTICLE

More From BioPortfolio on "AZ and Merck enter Lynparza alliance; Merck pays $1.6bn up front"

Quick Search
Advertisement
 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...